<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789009</url>
  </required_header>
  <id_info>
    <org_study_id>090030</org_study_id>
    <secondary_id>09-I-0030</secondary_id>
    <nct_id>NCT00789009</nct_id>
  </id_info>
  <brief_title>Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection</brief_title>
  <official_title>Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate HIV infection and associated conditions by monitoring infected&#xD;
      patients. The study will also serve as a means for recruiting HIV-infected individuals to&#xD;
      NIAIDs ongoing clinical and laboratory studies and supporting the institute s infectious&#xD;
      disease training program by providing Infectious Disease fellows with ongoing training in the&#xD;
      management of HIV infection.&#xD;
&#xD;
      People 18 years of age and older with suspected or confirmed HIV infection who live in the&#xD;
      Washington, D.C., metropolitan area may be eligible for this study. Physician referral is&#xD;
      required.&#xD;
&#xD;
      Participants come to the NIH Clinical Center a minimum of once every 3 to 4 months for&#xD;
      evaluation with a physical examination; blood tests for research purposes, safety, immune&#xD;
      status and viral load; and response to any treatment they may be receiving. Other procedures,&#xD;
      such as a biopsy, are done only as needed for standard medical practice, and informed consent&#xD;
      is obtained before any such procedure is done. Treatment offered is consistent with standard&#xD;
      medical practice; no experimental treatments are offered under this protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a prospective natural history study with ongoing monitoring of HIV&#xD;
      infection and HIV-related disease processes. The overall protocol Objective is to determine&#xD;
      the long-term clinical outcome of treated HIV infection and investigate aspects of the host&#xD;
      immune response that may predict outcomes. Minimal studies scheduled for each visit include:&#xD;
      monitoring of immune status and viral load, routine safety laboratory tests, and collection&#xD;
      of blood for research and storage. Medical treatment of HIV infection will be provided in&#xD;
      accordance with standard medical practice. Specific HIV treatment regimens will be in&#xD;
      accordance with standard medical practice and not constitute research.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2008</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>This study will provide a clinically well-characterized cohort of HIV infected individuals to support ongoing clinical and laboratory based NIAID intramural research programs described above.</measure>
    <time_frame>Every 3 to 6 months</time_frame>
    <description>Laboratory results and clinical data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>This study will support the NIAID Infectious Disease training program by providing fellows with ongoing training in the management of HIV infection.</measure>
    <time_frame>Yearly</time_frame>
    <description>Training</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Consist of HIV positive patients recruited from the Washington DC metropolitan area who will receive long-term care for their HIV infection through the NIAID/CCMD HIV clinic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Patients with known or suspected HIV infection, referred to a NIAID/CCMD investigator for reasons such as testing to diagnose or exclude HIV disease or assistance with HIV-related problems.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The first subgroup will consist of patients recruited from the Washington DC metropolitan&#xD;
        area who will receive long-term care for their HIV infection through the NIAID/CCMD HIV&#xD;
        clinic. The second subgroup will consist of patients with known or suspected HIV infection&#xD;
        who have been referred to a NIAID/CCMD investigator for reasons such as further testing to&#xD;
        diagnose or exclude HIV disease, assistance with the diagnosis or management of acute&#xD;
        HIV-related problems. This latter subgroup of patients will be followed on a short-term (12&#xD;
        months or less). Following discharge from the protocol, Group II patients will be returned&#xD;
        to the care of their referring physicians.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Patients are subject to selection by the Principal Investigator, and will satisfy all of&#xD;
        the following inclusion criteria:&#xD;
&#xD;
          1. HIV-infection as documented by positive HIV ELISA and Western Blot or positive assay&#xD;
             for HIV RNA (serum or plasma). Patients may also be included if they have laboratory&#xD;
             or clinical evidence suggestive of possible HIV-infection.&#xD;
&#xD;
          2. Age 18 years or older.&#xD;
&#xD;
          3. Ability and willingness of subject to understand study requirements and give written&#xD;
             informed consent.&#xD;
&#xD;
          4. Group I patients are required to have a primary care provider outside NIH to manage&#xD;
             non-HIV medical problems. Group II patients must have a referring physician or clinic&#xD;
             that will continue to manage HIV and non-HIV medical care.&#xD;
&#xD;
          5. For Group I patients, residence within the greater Washington DC area (approximately&#xD;
             within a 100-mile radius of the NIH Bethesda campus) is required.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        A prospective study subject will be ineligible for this study if he or she satisfies either&#xD;
        of the following criteria:&#xD;
&#xD;
          1. Has active drug or alcohol use or dependence or any other condition that, in the&#xD;
             opinion of the investigator, would interfere with adherence to study requirements.&#xD;
&#xD;
          2. Refuses to allow collection and storage of samples for research purposes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael C Sneller, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bryan P Higgins, R.N.</last_name>
    <phone>(301) 761-7395</phone>
    <email>bryan.higgins@nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael C Sneller, M.D.</last_name>
    <phone>(301) 496-0491</phone>
    <email>msneller@niaid.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2009-I-0030.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Aberg JA, Gallant JE, Anderson J, Oleske JM, Libman H, Currier JS, Stone VE, Kaplan JE; HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2004 Sep 1;39(5):609-29. Epub 2004 Aug 11.</citation>
    <PMID>15356773</PMID>
  </reference>
  <reference>
    <citation>Dub√© MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ; Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003 Sep 1;37(5):613-27. Epub 2003 Aug 15. Review.</citation>
    <PMID>12942391</PMID>
  </reference>
  <reference>
    <citation>Le Saout C, Hasley RB, Imamichi H, Tcheung L, Hu Z, Luckey MA, Park JH, Durum SK, Smith M, Rupert AW, Sneller MC, Lane HC, Catalfamo M. Chronic exposure to type-I IFN under lymphopenic conditions alters CD4 T cell homeostasis. PLoS Pathog. 2014 Mar 6;10(3):e1003976. doi: 10.1371/journal.ppat.1003976. eCollection 2014 Mar.</citation>
    <PMID>24603698</PMID>
  </reference>
  <verification_date>August 20, 2021</verification_date>
  <study_first_submitted>November 8, 2008</study_first_submitted>
  <study_first_submitted_qc>November 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2008</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opportunistic Infections</keyword>
  <keyword>AIDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

